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Bovine α-lactalbumin (α-La) contains numerous dipeptidyl peptidase IV (DPP-IV) inhibitory peptides sequences within its 
primary structure. In silico analysis indicated that the targeted hydrolysis of α-La with elastase should release DPP-IV 
inhibitory peptide sequences. An α-La isolate was hydrolysed with elastase under different conditions using an 
experimental design approach incorporating 3 factors (temperature, pH and enzyme to substrate ratio (E:S) ratio) at 2 
levels. The hydrolyzate generated at pH 8.5, 50C, E:S 2.0% (w/w) (H9) displayed the lowest half maximal DPP-IV inhibitory 
concentration (IC50 = 1.20 ± 0.12 mg mL
-1). Five α-La-derived DPP-IV inhibitory peptides (GY, GL, GI, NY and WL) predicted 
to be released in silico were identified by liquid-chromatography tandem mass spectrometry (LC-MS/MS) within H9 and its 
simulated gastrointestinal digestion (SGID) sample. This proof of concept study demonstrated the benefit of using a 




Dipeptidyl peptidase IV (DPP-IV) is an ubiquitous enzyme 
which is responsible for the cleavage and inactivation of the 
incretin hormones, glucose dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) 
1
. In the 
context of type 2 diabetes management, DPP-IV inhibition may 
be used as a means to improve the regulation of serum 
glucose in humans. Various DPP-IV inhibitory drugs (gliptins), 
have been developed to maintain the insulinotropic activity of 
the incretins in the post-prandial phase 
2
. 
Dietary components, including food protein-derived peptides, 
have been shown to play a role in the inhibition of DPP-IV in 
vitro and in certain instances in vivo, for reviews, see: 
3,4,5
. In 
silico studies have shown that selected DPP-IV inhibitory 
peptide sequences may be found within a wide range of 
dietary proteins 
6,7
. To date, milk proteins appear to be the 
most frequently studied substrate for the generation of DPP-IV 
inhibitory peptides. Depending on the enzymatic strategy 
employed, different milk proteins may appear to be more 
suitable substrates for the production of DPP-IV inhibitory 
peptides. For instance, it was recently predicted by Tulipano et 
al. 
8
 using in silico digestion with gastrointestinal proteinases 
that -lactoglobulin (-Lg) should yield a higher number of 
previously identified DPP-IV inhibitory peptides than -La. This 
was further confirmed following in vitro digestion of -Lg and 
-La with gastrointestinal enzymes, yielding hydrolyzates with 




. Other in 
silico analysis of the major milk proteins indicated that -
lactalbumin (-La) displayed the highest level of sequence 
coverage (43.9%) for previously identified DPP-IV inhibitory 









. It has been suggested that 
discrepancies between studies to determine the most 
adequate substrate for the generation of DPP-IV inhibitory 
peptides may arise from the lack of information on a wide set 
of DPP-IV inhibitory peptide sequences as well as their 
potency. For this reason, Lan et al., 
9
 have developed a peptide 
library approach incorporating 337 dipeptides which were 
evaluated for their in vitro DPP-IV inhibitory properties. 
It was hypothesized within this study that selected DPP-IV 
inhibitory peptide sequences within -La may be released 
during hydrolysis by careful selection of the enzyme activity. 
Therefore, the aim of this proof of concept study was to 
predict the most appropriate enzyme(s) for the release of 
selected DPP-IV inhibitory peptides from bovine -La and to 
subsequently validate the release of these peptides in vitro. 
This was achieved by (1) in silico prediction of the enzyme 
activity which should yield the highest number of known DPP-
IV inhibitory peptides, (2) hydrolysis of -La with this enzyme 
activity using an experimental design (3 factors (temperature, 
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pH and E:S ratio) studied at 2 levels) approach to optimize 
release of the predicted peptides and (3) confirmation of the 
release of the predicted peptides by liquid chromatography-
tandem mass spectrometric (LC-MS/MS) analysis. In addition, 
in vitro simulated gastrointestinal digestion (SGID) was used to 
study the stability of the DPP-IV inhibitory activity in selected 
hydrolyzates. 
Materials and methods 
Reagents 
Trifluoroacetic acid (TFA), tris(hydroxymethyl)aminomethane 
(TRIS), sodium phosphate monobasic, sodium phosphate 
dibasic, citric acid, calcium chloride (CaCl2), sodium chloride 
(NaCl), Gly-Pro p-nitroanilide (pNA), L, diprotin A (IPI) and 
porcine DPP-IV (≥ 10 units mg
-1
 protein) were obtained from 
Sigma-Aldrich (Dublin, Ireland). 2,4,6-Trinitrobenzenesulfonic 
acid (TNBS) was from Pierce Biotechnology (Medical Supply, 
Dublin, Ireland). Hydrochloric acid (HCl), sodium hydroxide 
(NaOH), high performance liquid chromatography (HPLC) 
grade water and acetonitrile (ACN) were from VWR (Dublin, 
Ireland). Whey protein concentrate 80 (WPC80, 81.1% (w/w) 
protein) was obtained from Carbery Ingredients (Ballineen, 
Ireland). Porcine elastase ( 5 U mg
-1
 protein) was obtained 
from My Biosource (catalog # MBS173124, San Diego, CA, 
USA), pepsin (3000 FCC U g
-1
) from Biocatalysts (Cefn Coed, 
Wales, UK) and Corolase PP (2500 UHb g
-1
) from AB Enzymes 
(Darmstadtd, Germany). All other reagents were of analytical 
grade and were obtained from Sigma-Aldrich. 
In silico analysis 
In silico digestion of bovine -La with pepsin, trypsin, 
chymotrypsin, elastase and glutamyl endopeptidase was 
carried out with the peptide cutter program available in 
Matlab (version R2014b, MathWorks, Inc, Natick, MA, USA), 
using the same cleavage rules as per ExPASy. Comparison of 
the peptide sequences predicted to be released to known DPP-
IV inhibitory peptides previously identified in the literature 
7,9
 
was then carried out. 
Extraction of -La from WPC80 
-La was extracted from WPC80 following the method 
described by Fernández, et al. 
10
, with modifications. Briefly, -
La was selectively precipitated by adjusting the pH of WPC80 
to 3.5 with a 1 M citric acid solution. The pellet was washed 3 
times and then resolubilized using a 0.1 M CaCl2 solution at pH 
7.5 in a 1:1 (w:w) ratio. The -La extract was then dialyzed 
with distilled water (18 h, 4°C, snake skin dialysis tubing 10 kDa 
nominal molecular weight cut-off, Fisher Scientific). The 
samples were freeze-dried (FreeZone 18L, Labconco, Kansas 
City, MO, USA) and stored at -20°C until further analysis. 
The protein content of the -La isolate was determined with 
the bicinchoninic acid (BCA) method using a Micro BCA
TM 
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The -
La content of the isolate was determined by reverse-phase 
high-performance liquid chromatography (RP-HPLC) as 
described by Nongonierma and FitzGerald 
11
, using an -La 
standard sample (Sigma-Aldrich). The extraction yield and the 




Enzymatic hydrolysis of the -La isolate and in vitro simulated 
gastrointestinal digestion (SGID) of the hydrolyzates 
The outcome of the in silico analysis indicated that incubation 
of -La with elastase should release the greatest number of 
DPP-IV inhibitory peptides (Table 1). Therefore, digestion of -
La with elastase was carried out following a proof of concept 
experimental design approach (yielding hydrolyzates H1-H9). 
The parameters of the experimental design used for -La 
hydrolysis with elastase consisted of the pH, temperature and 
E:S studied at two levels (Supplementary Table S1). These 
parameters were specifically chosen as they are key 
determinants of peptide release during enzymatic digestion. 
The pH (7.0-8.5) and temperature (37-50C) range were 
selected based on the optimum values for elastase as 
indicated by the supplier. The E:S ratio (1-2% (w/w)) was 
chosen based on levels which have previously been reported 
for the hydrolysis of whey proteins with pancreatic enzymes 
13
. 
Each hydrolyzate was generated once with the exception of 
the central point condition (H5, pH 7.8 (0), 44C (0) and E:S 
1.5% (0)) which was generated as two independent duplicates 
(H5(1) and H5(2)). 
The -La isolate was resuspended (50 g L
-1
 on a protein basis) 
in distilled water and was incubated for 30 min in a water bath 
at the desired temperature and pH as per the experimental 
design conditions. Elastase was then added to the -La 
suspension at the desired E:S and hydrolysis was carried out 
for 4 h. The pH was maintained constant by adding 0.1 M 
NaOH with a pH stat (Titrando 843, Tiamo 1.4 Metrohm, 
Dublin, Ireland). The enzyme was then heat inactivated at 90°C 
for 20 min. A control sample of unhydrolyzed -La underwent 
the same conditions as the hydrolyzate with the exception that 
it did not contain enzyme. 
H9 was subsequently subjected to in vitro SGID as described by 
Walsh et al. 
14
. Briefly, the hydrolyzate was incubated at 37C 
with pepsin (E:S 1%, pH 2.0) for 90 min followed by incubation 
with Corolase PP (E:S 2.5%, pH 7.5) for another 150 min. The 
pH was maintained constant during the SGID steps using a pH 
stat (Metrohm). 
All hydrolyzates were freeze-dried post heat-inactivation and 
stored at -20°C prior to further analysis. 
DPP-IV inhibition assay 
The protein hydrolyzates were dispersed in HPLC grade water 
at 3.1 mg mL
-1
 (final concentration). The DPP-IV inhibition 
assay was carried out in triplicate as described by 
Nongonierma and FitzGerald 
15
. Briefly, 25 μL sample were 
pipetted onto a 96 well microplate (Sarstedt, Dublin, Ireland) 
containing Gly-Pro-pNA (final concentration 0.200 mM). The 
negative control contained 100 mM Tris-HCl buffer pH 8.0 (25 
μL) and Gly-Pro-pNA. The reaction was started by the addition 
of DPP-IV (final concentration 0.0025 U mL
-1
). The positive 
control was diprotin A. The microplate was incubated at 37C 
for 60 min in a microplate reader (Biotek Synergy HT, 
Winoosky, VT, USA), and the absorbance of the released pNA 
was monitored at 405 nm. 
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Table 1 Peptides predicted to be released in silico from -lactalbumin (-La) by elastase using the peptide cutter facility of Matlab and peptides identified within the hydrolyzate by 
reverse-phase ultra-performance tandem mass spectrometry (RP-UPLC MS/MS). The half maximal inhibitory concentration (IC50) value of the peptide is provided when available in the 
literature. 
Peptide sequence* Mw+H (Da) Detected by LC-MS/MS DPP-IV IC50 (µM)
*** Reference 
H9 SGID H9 
EQL 389.20   - - 
TKC(CEKL)EV** 1050.51 nd nd - - 
FREL 564.31 nd nd - - 
KDL 375.22   - - 
KGY 367.20   - - 
GGV 232.13 nd nd - - 
PEWV 530.26   - - 
C(CS)TTFHTS** 984.37 nd nd - - 
GY 239.10   na 9 
DTQA 434.19   - - 
QNNDS 577.22 nd nd - - 
TEY 412.17 nd  - - 
GL 189.12   2615.0 15 
FQI 407.23   - - 
NNKI 488.28  nd - - 
WC(CDKFL)KDDQNPHSS** 1920.82 nd nd - - 
NI 246.15   - - 
C(MCV)NI** 680.27 nd nd - - 
DDDL 477.18 nd nd - - 
TDDI 463.20 nd  - - 
KKI 388.29   - - 
DKV 361.21   - - 
GI 189.12   na 9 
NY 296.12   na 9 
WL 318.18   43.6 16 
HKA 355.21   - - 
EKL 389.24   - - 
DQWL 561.27   - - 
nd: not detected; na: not available. 
*Peptide sequence with the one letter code. 
**A disulphide bridge is present between cysteine (C) residues within the peptide. 
***The DPP-IV inhibition reported by Lan, et al. 9 were < 35% when the peptides were tested at 100 µM. 
For the hydrolyzates displaying DPP-IV inhibition > 50 % at 3.1 
mg mL
-1
, the DPP-IV IC50 values were determined by plotting 
the dose-response curve (at concentrations ranging from 3.1 × 
10
-2
 to 3.1 mg mL
-1
). Each analysis was conducted in triplicate 
(n = 3). 
Determination of the degree of hydrolysis (DH) 
The DH was determined following the method of Adler-Nissen 
17
, essentially as described in Nongonierma and FitzGerald 
13
. 
Each experiment was carried out in triplicate (n = 3). 
Gel permeation high performance liquid chromatography (GP-
HPLC) and reverse-phase ultraperformance liquid chromatography 
(RP-UPLC) of the hydrolyzates 
The -La hydrolyzates were analyzed by GP-HPLC as described 
in Spellman, et al. 
18
. The peptide profile of the -La 
hydrolyzates was determined by RP-UPLC as described in 
Nongonierma and FitzGerald 
13
. 
LC-MS/MS of the -La hydrolyzates 
Samples were analyzed by LC-MS/MS using an Acquity UPLC 
(Waters, Milford, MA, USA) coupled to a quadrupole time-of-
flight mass spectrometer (Q-TOF, Impact HD™, Bruker 
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Daltonics GmbH, Bremen, Germany). The MS was fitted with 
an electrospray ionization (ESI) source used in positive ion 
mode. Hystar software (Bruker Daltonics) was used to control 
the instruments and to acquire data. Chromatographic 
separation was carried out on an Acquity BEH amide column 
(Waters) as described by Le Maux, et al. 
19
. Fifty micrograms of 
sample (final concentration: 5 g L
-1
, injection volume: 10 µL) 
were injected onto the column. MS measurements were 
performed over a 70-2500 m/z acquisition range. MS data 
were processed on Compass DataAnalysis 4.0 SP5 (Bruker 
Daltonics). 
Peptide sequences predicted to be present by in silico model 
were searched for within hydrolyzate samples using the 
strategy described by Le Maux, et al. 
19
. A mass tolerance of 
0.1 Da and a time difference between the observed and 
predicted retention times was set at a maximum of 16 min. 
Peptide peak intensities in H9 and its SGID sample were 
visualized on Venn diagrams. MS data was analyzed using 
ProfileAnalysis (Bruker Daltonics) and Matlab. More than 500 
compounds were detected in each sample but only peaks with 
an intensity > 5 × 10
5
 were analyzed. The peptides observed 
within each sample were classified as follows: when peptide 
peaks had similar intensities in both samples, they were 
reported at the intersection of the Venn diagram and when 
peptide peaks within a sample had different intensities 
compared to the other sample (> 3 fold difference), they were 
reported outside of the intersection of the Venn diagram. 
Statistical analysis 
ANOVA was used to assess the effect of the parameters (pH, 
temperature and E:S) of the experimental design on DPP-IV 
inhibition when evaluated at 3.1 mg mL
-1
 at a significance level 
p < 0.05. The effects of the experimental design parameters on 
DPP-IV inhibition were tested (p < 0.05) using a multi-linear 
regression (MLR) model (complete model, eqn 1) as follows: 
Y = β0 + β1pH + β2T + β3ES +  ε                                                   (1) 
With Y, the DPP-IV inhibition of the -La hydrolyzates at 3.1 
mg mL 
-1
; β0 to β3: the coefficients of the model; pH, T 
(temperature) and ES (E:S): the z-centered parameters of the 
experimental design and ε: the residual of the model. 
 
The model was further optimized (simplified model) by only 
taking into account the parameters which were significant (p < 
0.1) as described by van der Ven, et al. 
20
. A response surface 
methodology (RSM) curve was plotted using the simplified 
model with Matlab. 
The statistical treatment for DH was carried out with a one 
way ANOVA followed by a Student Newman-Keuls test used 
for multiple means comparison (p < 0.05). Statistical analyses 
were carried out with SPSS (version 22, SPSS Inc., Chicago, IL, 
USA). 
Results 
In silico digestion of -La 
Hydrolysis of -La by five different enzyme activities (pepsin, 
trypsin, chymotrypsin, elastase and glutamyl endopeptidase) 
showed that elastase allowed the release of the highest 
number of previously identified DPP-IV inhibitory peptides 
(Supplementary Table S2 and Table 1). Previous studies have 
suggested that specific amino acids within peptide sequences 
correlated with DPP-IV inhibition. For instance W at position 1 
and P/A at position 2 are frequently found in DPP-IV inhibitory 
peptides with IC50 values < 200 µM 
7,8
. The in silico analysis did 
not show any peptides with a P at position 2 while two 
peptides with an A at position 2 were predicted to be released 
by following in silico digestion of -La with chymotrypsin low 
(KAL, (f 108-110)) and high (LAHKALCSEKLDQW, (f 105-118)) 
specificity. In addition, three peptides with a N-terminal W 
were identified following in silico digestion of -La with 
glutamyl endopeptidase (WVCTTFHTSGYDTQAIVQNNDSTE, (f 
26-49)), pepsin (WCKDDQNPHSSNICNISCDK, (f 60-79)) and 
elastase (WL, (f 118-119)). 
Five previously identified DPP-IV inhibitory dipeptides (GY, GL, 
GI, NY and WL) were predicted to be released following in 
silico digestion of -La by elastase (Table 1). Of the peptides 
predicted to be released by elastase, WL is a relatively potent 
DPP-IV inhibitory peptide with an IC50 of 43.6 µM 
16
. Overall, of 
the enzymes studied, elastase was predicted to release the 
highest number of previously identified DPP-IV inhibitory 
peptides or peptides with DPP-IV inhibitory motifs (with a W at 
the N-terminus). Therefore, -La was digested with elastase to 
verify if these in silico predictions translated in vitro. 
DPP-IV inhibitory activity of the -La hydrolyzates generated 
within the experimental design conditions 
As already outlined, -La was isolated from WPC80. The RP-
UPLC profile of the starting WPC80 and the -La isolate are 
displayed in Supplementary Fig. S1. The isolate enriched in -
La had a purity and yield of 79.3 ± 0.2 and 40.3 ± 1.4% (w/w), 
respectively. 
The generation of the hydrolyzates was reproducible as 
indicated by the lack of significant differences (p > 0.05) 
between the two independent duplicates H5(1) and H5(2) in 
terms of their DH, DPP-IV inhibition at 3.1 mg mL
-1
 and their 
DPP-IV IC50 values (Table 2). 
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Table 2 Degree of hydrolysis (DH), dipeptidyl peptidase IV (DPP-IV) inhibition of the -lactalbumin (-La) hydrolyzates evaluated at 3.1 mg mL-1 and DPP-IV half maximal inhibitory 
concentration (IC50) of the hydrolyzates. 
Hydrolyzate Hydrolysis conditions with elastase* DH (%)** DPP-IV inhibition at 
3.1 mg mL-1 (%)** 
DPP-IV IC50  
(mg mL-1)** pH Temperature (°C) E:S (%) 
H1 7.0 (-1) 37 (-1) 1.0 (-1) 11.9  2.5a,b 34.7  5.9a > 3.13 
H2 7.0 (-1) 37 (-1) 2.0 (1) 15.0  0.5c,d 38.9  8.2a,b > 3.13 
H3 8.5 (1) 37 (-1) 1.0 (-1) 10.9  0.2a 23.0  6.7a > 3.13 
H4 8.5 (1) 37 (-1) 2.0 (1) 13.4  0.6a,b,c,d 38.8  2.9a,b > 3.13 
H5 (1) 7.8 (0) 44 (0) 1.5 (0) 14.0  0.5b,c,d 54.9  6.6b,c 2.07  0.30b 
H5 (2) 7.8 (0) 44 (0) 1.5 (0) 14.8  0.5b,c,d 56.2  10.7b,c 1.61  0.35a,b 
H6 7.0 (-1) 50 (1) 1.0 (-1) 12.7  0.5a,b,c 52.8  7.8 b,c 2.13  0.43b 
H7 7.0 (-1) 50 (1) 2.0 (1) 16.2  0.9d 62.7  6.9c 1.55  0.38a,b 
H8 8.5 (1) 50 (1) 1.0 (-1) 10.5  0.3a 55.7  3.2b,c 2.15  0.24b 
H9 8.5 (1) 50 (1) 2.0 (1) 18.9  2.4e 75.8  3.7d 1.20  0.12a 
*The z-centered values of the experimental design parameters are given into brackets. 
**Mean  SD (n=3). Within the same column, values with different superscript letters are significantly different (p < 0.05). 
 
The hydrolyzates generated at 37C (H1-H4) yielded DPP-IV 
inhibition < 50 % at the highest concentration tested (3.1 mg 
mL
-1
), resulting in it not being possible to compare all 
hydrolyzates based on their DPP-IV IC50 value. Therefore, 
hydrolyzates were compared using the % DPP-IV inhibition 
observed at 3.1 mg mL
-1
. The DPP-IV inhibition (at 3.1 mg mL
-1
) 
of the hydrolyzates varied between 23.0  6.7 and 75.8  3.7% 
for H3 and H9, respectively (Table 2). H9 had the lowest IC50 
value (1.20  0.12 mg mL
-1
). 
Modelling and RSM of the DPP-IV inhibitory properties of the -La 
hydrolyzates generated within the experimental design conditions 
A good correlation was obtained between the DPP-IV 
inhibition observed at 3.1 mg mL
-1
 and the parameters of the 
experimental design in the complete model (R
2
 = 0.897, p = 
0.00664). Temperature and E:S significantly (p < 0.05) effected 
DPP-IV inhibition (Table 3). 
Given the apparent lack of a pH effect on DPP-IV inhibition, the 
simplified model was further optimized only taking into 
account temperature and E:S yielding an R
2
 = 0.896 (p = 
0.0011). Hydrolysis temperature was found to have the 
greatest impact on DPP-IV inhibition as indicated by the higher 
coefficient associated with this parameter in the simplified 
model (Table 3). The RSM curve generated with the simplified 
model illustrates the positive effect of both temperature and 
E:S on DPP-IV inhibition (Supplementary Fig. S2). Using this 
proof of concept experimental design, as expected, it was 
predicted with the models (Table 3) that highest DPP-IV 
inhibition would be obtained at the highest levels of pH, 
temperature and E:S ratio employed herein, i.e., pH 8.5, 50C 
and an E:S of 2% (w/w). These conditions corresponded to H9 
(pH 8.5, 50C and E:S of 2% (w/w)). 
Table 3 Multilinear regression (MLR) describing the dipeptidyl peptidase IV (DPP-IV) inhibition observed with -lactalbumin (-La) hydrolyzates evaluated at 3.1 mg mL-1, as a 
function of all parameters of the experimental design (complete model) and the most significant parameters (p < 0.01, simplified model). 
 Parameters Coefficient Estimate Standard error t value p* 
Complete model Intercept 48.59 2.2 22.29 3.38E-06 
 pH 0.54 2.3 0.23 0.826 
 Temperature 13.93 2.3 6.02 0.002 
 E:S 6.25 2.3 2.70 0.043 
  Root mean square error: 6.54; R2: 0.897; p model: 0.00664 
Simplified model Intercept 48.59 2.0 24.3 3.20E-07 
 Temperature 13.93 2.1 6.6 0.001 
 E:S 6.25 2.1 2.9 0.026 
  Root mean square error: 6.0; R2: 0.896; p model: 0.0011; p lack of fit: 0.5358. 
*p < 0.05 are significantly different from 0. 
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Fig. 1. Molecular mass distribution determined by gel permeation high performance liquid chromatography (GP-HPLC) of the peptides within the -lactalbumin (-La) 
hydrolyzates generated with elastase in the conditions of the experimental design.  
Physicochemical characteristics of the -La hydrolyzates 
The DH of the hydrolyzates (Table 2) varied between 10.5  0.3 
(H8) and 18.9  2.4% (H9). Differences in the peptide profile 
(Supplementary Fig. S2) and molecular mass distribution (Fig. 
1) of the hydrolyzates were seen. The molecular mass 
distribution profile showed significant protein breakdown in all 
hydrolyzates. Peptides were broken down to a higher extent in 
hydrolyzates generated at temperatures > 44C (H5-H9), with 
> 75% of the hydrolyzates having a molecular mass < 1 kDa. In 
the hydrolyzates generated at 37C (H1-H4), < 70% of the 
components had a molecular mass < 1 kDa (Fig. 1). 
DPP-IV inhibitory activity and physicochemical characteristics of 
the SGID sample of H9 
Since H9 displayed the highest in vitro DPP-IV inhibition (Table 
2), this hydrolyzate was subjected to SGID. The DPP-IV IC50 
value for the SGID of H9 was 1.53  0.11 mg mL
-1
. There was 
no significant difference (p > 0.05) between the IC50 value of 
H9 before and after SGID. 
Differences were seen in the peptide profile of H9 following 
SGID, generally resulting in the presence of more intense 
hydrophilic peptide peaks (Fig. 2A). A higher proportion of 
peptides < 1 kDa after SGID of H9 was seen (Fig. 2 B). 
Peptide detection within H9 and its SGID sample 
More than 500 compounds were detected in either H9 or its 
SGID sample. The peptides identified within H9 and its SGID 
sample ranged from 2 to 22 amino acids in length. Of the 28 
peptides predicted to be released in silico following complete 
digestion of -La by elastase, 18 were detected by LC-MS/MS 
within H9 (Table 1). As already indicated, the most abundant 
peptides, on the basis of their peak intensities, detected within 
H9 and its SGID sample were compared using a Venn diagram 
approach (Fig. 2C). Sixty four high intensity peaks were 
common between both samples, while 82 and 86 unique 
peptides were detected for H9 and its SGID, respectively. In 
addition, several of the peptides detected within H9 and its 
SGID samples, displayed the features of known-DPP-IV 
inhibitory peptides consisting of W at the N-terminus, P/A at 
position 2 or P at the C-terminus (Supplementary Table S3). 
Discussion 
-La has been shown to possess several relatively potent DPP-
IV inhibitory peptides within its sequence 
7
. Therefore, the 
development of enzymatic strategies for the targeted release 
of such peptides is of interest. The role of W-containing 
peptides in in vitro DPP-IV inhibition has been demonstrated 
21
. Interestingly, -La is the bovine milk protein with the 
highest W content. In silico digestion of -La was applied in 
order to predict the release of peptides which were then 
compared to known DPP-IV inhibitory peptides. Elastase has 
been shown to cleave at the C-terminal side of L, A, V and I 
22
. 
Experimental designs have previously been applied to optimize 
the release of milk protein-derived bioactive peptides, 
particularly for the generation of angiotensin converting 
enzyme (ACE) inhibitory and antioxidant peptides 
20,23-25
. To 
our knowledge, this approach has not been previously used in 
combination with in silico analysis to optimize the hydrolysis of 
food proteins for the generation of DPP-IV inhibitory peptides. 
It was found in this proof of concept study that temperature 
and E:S had a significant (p < 0.05, simplified model) effect on 
the release of DPP-IV inhibitory peptides, with the 
temperature having the highest effect (Table 3). This result is 
similar to an earlier study also showing that hydrolysis 
temperature played a greater role than the E:S in the release 
of antioxidant peptides upon hydrolysis of whey proteins with 
thermolysin 
23
. In contrast, Naik, et al. 
25
 reported that pH and 
E:S had an effect on the release of antioxidant peptides from 
whey proteins hydrolysed with trypsin, while temperature did 
not. 
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Fig. 2. (A) Reverse phase ultra-performance liquid chromatographic (RP-UPLC) profile, (B) molecular mass distribution by gel permeation high performance liquid 
chromatography (GP-HPLC) and (C) Venn diagrams of peptide peak intensities within the -lactalbumin (-La) hydrolyzate generated at pH 8.5, 50C, E:S 2% with 
elastase (H9) and of its simulated gastrointestinal digest (SGID). Peptide peaks highlighted with an arrow on the RP -UPLC profile of H9 differ from the SGID sample. 
ACN: acetonitrile. 
While no significant (p > 0.05) effect of hydrolysis pH on DPP-
IV inhibition was seen herein, some differences were visible in 
terms of the physicochemical characteristics of the 
hydrolyzates generated at different pHs (Fig. 1 and 
Supplementary Fig. S3). For example, for hydrolyzates 
generated at 50C and an E:S of 2%, differences in peptide 
peak intensities were seen between H7 (pH 7.0) and H9 (pH 
8.5), particularly at retention times of 0.6 and 7.7 min. 
Of the 28 predicted sequences, including disulfide linked 
peptides, only 18 peptides were detected in H9 (Table 1). This 
may arise from the fact that -La possesses secondary/tertiary 
structure, making it challenging to predict peptide release 
using peptide cutter programs which rely solely on the primary 
sequence of the protein. Furthermore, in silico digestion does 
not account for partial proteolysis. While combinations of in 
silico and in vitro approaches may be beneficial to develop 
bioactive dietary protein hydrolysates, some limitations exist. 
Cleavage specificity of enzymes generally only considers major 
cleavage sites. However, some secondary cleavage sites may 
exist, which are generally not taken into account in peptide 
cutter programmes. In addition, side activities may be found 
within enzyme preparations, which further yield to the release 
of peptide sequences which were not predicted to be released 
when using in silico digestion methods. Furthermore, 
protein/peptide digestion is highly dependent on the 
conditions employed during enzymatic hydrolysis (i.e., 
temperature, time, pH, E:S ratio, etc.).
20
 For all the above 
reasons, it is quite challenging to directly translate in silico 
predictions to actual in vitro peptide release. 
Numerous peptides identified within H9 were also detected in 
its SGID sample (Table 1). Five of these peptides (GY, GL, GI, NY 
and WL) were previously identified as DPP-IV inhibitors. 
Similarly, WV (f 24-25), a potent DPP-IV inhibitory peptide (IC50 
= 65.7 µM 
15
) was also identified by LC-MS/MS within the two 
samples (data not shown). In addition, several peptides within 
these two samples displayed the features of previously 
identified DPP-IV inhibitory peptides. However, these 
additional peptides may have only been present at low 
concentrations as none of these appear to originate from -La 
(Supplementary Table S3). Therefore, it is expected that their 
contribution to the overall DPP-IV inhibition is minor. Thus, the 
peptides GY, GL, GI, NY, WL and WV may, in part, be 
responsible for the DPP-IV inhibitory properties of the 
hydrolyzates. Quantification of these peptides within the 
hydrolyzate samples may help to better understand their 
overall contribution to the DPP-IV inhibition observed and also 
to determine their extent of release from -La following 
enzymatic digestion. However, peptide quantification was not 
embarked upon during the present study. 
To date, two studies have shown that ingestion of DPP-IV 
inhibitory milk protein hydrolyzates in vivo could reduce serum 
glucose level in small animals 
26,27
. A direct link with in vivo 
DPP-IV inhibition had not been established in these studies. 







 and fish skin gelatin hydrolyzates 
31,32
 showed 
inhibition of plasma DPP-IV activity. Ultrafiltration fractions of 
hydrolyzates with DPP-IV IC50 values between ~ 1 to 3 mg mL
-1
 
have been shown to increase plasma DPP-IV inhibition and 
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(OGTT) in small animals 
30-32
. The most potent DPP-IV 
inhibitory hydrolyzate herein, H9, had an IC50 of 1.20  0.12 mg 
mL
-1
. Based on the positive outcomes of previous studies with 
similar in vitro DPP-IV inhibitory potencies, H9 may have the 
potential to yield positive effects in vivo. 
No significant modification of the DPP-IV inhibitory properties 
were seen herein following SGID of H9 (IC50 of 1.20  0.12 and 




p > 0.05, for H9 and its SGID sample, 
respectively). However, the RP-UPLC and molecular mass 
distribution profiles of H9 and its SGID sample differed (Fig. 2A 
and 2B). Furthermore, major differences in terms of peptide 
peak intensities were observed before and after SGID (Fig. 2C). 
This indicates that the peptides within H9 were significantly 
degraded during incubation with the gastrointestinal enzymes. 
Conclusion 
In silico analyses based on a peptide cutter approach allowed 
the design of a proof of concept experimental procedure to 
specifically release previously identified DPP-IV inhibitory 
peptides from -La. Hydrolysis with elastase was predicted to 
release five previously identified DPP-IV inhibitory peptides 
(i.e., GY, GL, GI, NY and WL). During in vitro enzymatic 
digestion of -La with elastase, temperature had the highest 
effect (p < 0.05) on the release of DPP-IV inhibitory peptides 
followed by the E:S (p < 0.05). Several previously identified 
DPP-IV inhibitory peptides were observed by LC-MS/MS in the 
most potent DPP-IV inhibitory -La hydrolyzate, H9. Following 
SGID, major differences were seen in the peptides within H9. 
However, potent DPP-IV inhibitory activity was also found 
within the SGID sample, showing promise in terms of the 
potential oral application of H9 as an ingredient for serum 
glucose lowering properties in humans. In vivo assessment of 
the hydrolyzates is required to evaluate their potential role as 
DPP-IV inhibitors in humans. 
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Supplementary data 
Supplementary Table S1. Details of the hydrolysis parameters used to generate the hydrolyzate samples, including the parameters used in the experimental design 
(hydrolyzates highlighted in grey) applied during -lactalbumin (-La) hydrolysis with elastase. 
Experiment Hydrolysis conditions with elastase 
pH Temperature (°C) E:S (%) 
H1 7.0 (-1) 37 (-1) 1.0 (-1) 
H2 7.0 (-1) 37 (-1) 2.0 (1) 
H3 8.5 (1) 37 (-1) 1.0 (-1) 
H4 8.5 (1) 37 (-1) 2.0 (1) 
H5 7.8 (0) 44 (0) 1.5 (0) 
H6 7.0 (-1) 50 (1) 1.0 (-1) 
H7 7.0 (-1) 50 (1) 2.0 (1) 
H8 8.5 (1) 50 (1) 1.0 (-1) 
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Supplementary Table S2. Results of the in silico digestion of -lactalbumin (-La) with pepsin, trypsin, chymotrypsin and glutamyl endopeptidase. 
Enzyme* Peptide sequence** Previously identified DPP-IV 
inhibitor 
PEPS EQL  
PEPS TKCEV  
PEPS RE  
PEPS LKD  
PEPS LKG  
PEPS YGGVSL  
PEPS PEW  
PEPS VCTT  
PEPS HTSG  
PEPS DTQAIVQNNDSTE  
PEPS QINNKI  
PEPS WCKDDQNPHSSNICNISCDK  
PEPS LDDD  
PEPS TDDIMCVKKILDKVGIN  
PEPS AHKALCSEK  
PEPS DQ  
PEPS CEKL  
PEPS2 EQL  
PEPS2 TKCEV  
PEPS2 RE  
PEPS2 LKD  
PEPS2 LKGYGGVSL  
PEPS2 PEWVCTT  
PEPS2 HTSGYDTQAIVQNNDSTEYG  
PEPS2 QINNKIWCKDDQNPHSSNICNISCDK  
PEPS2 LDDD  
PEPS2 TDDIMCVKKILDKVGINYW  
PEPS2 AHKALCSEK  
PEPS2 DQW  
PEPS2 CEKL  
TRYPS EQLTK  
TRYPS CEVFR  
TRYPS ELK  
TRYPS DLK  
TRYPS GYGGVSLPEWVCTTFHTSGYDTQAIVQNNDSTEYGLFQINNK  
TRYPS IWCK  
TRYPS DDQNPHSSNICNISCDK  
TRYPS FLDDDLTDDIMCVK  
TRYPS ILDK  
TRYPS VGINYWLAHK  
TRYPS ALCSEK  
TRYPS LDQWLCEK  
CH-HI EQLTKCEVF  
CH-HI RELKDLKGY  
CH-HI GGVSLPEW  
CH-HI VCTTF  
CH-HI HTSGY  
CH-HI DTQAIVQNNDSTEY  
CH-HI GLF  
CH-HI QINNKIW  
CH-HI CKDDQNPHSSNICNISCDKF  
CH-HI LDDDLTDDIMCVKKILDKVGINY  
CH-HI LAHKALCSEKLDQW  
CH-HI LCEKL  
CH-LO EQL  
CH-LO TKCEVF  
CH-LO REL  
CH-LO KDL  
CH-LO KGY  
CH-LO GGVSLPEW  
CH-LO VCTTF  
CH-LO TSGY  
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CH-LO DTQAIVQNNDSTEY  
CH-LO GL  
CH-LO QINNKIW  
CH-LO CKDDQNPH  
CH-LO SSNICNISCDKF  
CH-LO DDDL  
CH-LO TDDIM  
CH-LO CVKKIL  
CH-LO DKVGINY  
CH-LO AH  
CH-LO KAL  
CH-LO CSEKL  
CH-LO DQW  
CH-LO CEKL  
GLUEND QLTKCE  
GLUEND VFRE  
GLUEND LKDLKGYGGVSLPE  




GLUEND KLDQWLCE  
GLUEND KL  
 
*PEPS: pepsin pH 1.3; PEPS2: pepsin pH > 2; TRYPS: trypsin; CH-HI: chymotrypsin high specificity; CH-LO: chymotrypsin low specificity; GLUEND: glutamyl 
endopeptidase. 
**Peptide sequence abbreviated with the one letter amino acid code. 
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Supplementary Table S3. Peptide sequences identified by LC-MS within the -lactalbumin (-La) H9 and its associated simulated gastrointestinal digest (SGID) sample, which present structural features of known dipeptidyl peptidase IV 
inhibitory peptides (i.e., W at the N-terminus, P/A at position 2 or P at the C-terminus 7,8,33). These peptides have not previously been evaluated for their DPP-IV inhibitory potential, therefore, their DPP-IV inhibitory properties are not 
known. 
Feature Peptide sequence* Parent protein** Fragment 
Identified in 
H9 SGID of H9 
N-terminal W WGAVLL    
 
WGLF    
P at position 2 EPMLGV    
 
HPHAY     
 
KPTPE -Lg f(47-51)  
 
KPTPEGDL -Lg f(47-54)  
 
KPTPEGDLE -Lg f(47-55)  
 
KPTPEGDLEL -Lg f(47-56)  
 
KPTPEGDLEI -Lg f(47-56)  
 
MPEATLGAAFKF     
 
MPEGGKKPM     
 
MPFSPPRA     
 
MPKEQDSVY    
 
MPPEV    
 
MPVVCLSQM     
 
PPPVSLPADE    
 
QPQSQ     
 
SPPSVT     
 
TPEVD -Lg f(125-129)  
 
TPEVDD -Lg f(125-130)  
 
TPEVDDE -Lg f(125-131)  
 
TPEVDDEA -Lg f(125-132)  
 
TPEVDDEAL -Lg f(125-133)  
 
TPEVDDEALE -Lg f(125-134)  
 
TPEVDDEALEK -Lg f(125-135)  
 
TPLPL    
 
VPYPQ -CN f(178-182)  
 
YPSYG κ-CN f(35-39)   
 
NPWDQV s2-CN f(107-112)  
A at position 2 AAAFKALAEAGL     
 
AANTVYPL    
 
AATVALL    
 
CAGLDLQ     
 
DAGLLV    
 
DAFLGSFLYEYSR BSA f(329-341)  
 
DAIPENLPPLTA BSA f(301-312)  
 
DALNEN -Lg f(85-90)  
 
DAQSAPL -Lg f(33-39)  
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EAAVK     
 
EAGLV    
 
EALPH    
 
EASVPE    
 
FAGKN    
 
FASQY     
 
LAPHCDKL     
 
LAPPQEEL    
 
LAQSVT    
 
LAQSVTLNSYVQLGVLPR    
 
MAGGGSGLV    
 
MAGSASPK     
 
MAGSGGRL     
 
MALPPK κ-CN f(106-111)  
 
MALRN     
 
MAVLVL     
 
RATDATAL     
 
SAEPEQS -Lg f(110-106)  
 
SAPFPS     
 
SAPSVT     
 
SASSPLLSTK     
 
TASSGLT     
 
TAVQGSKP     
 
VAGTK     
 
VAPFDPLFG    
 VAPFPEV s1-CN f(25-31)  
 
VAPFTVSNAG    
 
VAYGGV    
 
YAASSYLSLTSSDWK     
 
YAKPA κ-CN f(61-65)   
C-terminal P AVGEPLP    
 
EMPFKP     
 
ESGPSLVSKP    
 
FLAAFMP    
 
FNTP     
 
FYDP    
 
HKKP    
 
HLPLP -CN f(134-138)  
 
HYTALP     
 
LFPGNTSVKP    
 
LGGPGLP    
 
LVVHP    
 
LVYPFPGLP    
 
MHQHP     
Journal Name  ARTICLE 
 15 
Please do not adjust margins 
Please do not adjust margins 
 
NKPALAGMP     
 
NMMDVGVMP    
 
SELSALP    
 
SVYPFPGLP     
 
TAVQGSKP     
 
TFDLP    
 
TMTLGTFP    
 
VSGGLP     
 
VTHFP    
 
VVAGALLPP     
 
SLELYP     
 
*Peptide sequences abbreviated with the one letter amino acid code. 
**-Lg: -lactoglobulin; BSA: bovine serum albumin; CN: casein 
1. G. Tulipano, L. Faggi, A. Nardone, D. Cocchi and A. M. Caroli, Int. Dairy J., 2015, 48, 62-72. 
2. A. B. Nongonierma and R. J. FitzGerald, Food Chem., 2014, 165, 489–498. 
3. A. B. Nongonierma and R. J. FitzGerald, J. Funct. Foods, 2013, 5, 1909–1917. 
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Supplementary Fig. S1. Reverse phase ultra-performance liquid chromatographic (RP-UPLC) profile of the whey protein concentrate 80 (WPC 80) and the -
lactalbumin (-La) isolate. 
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The peptide profiles (RP-UPLC) of H4, H7, H8 and H9 are depicted on Supplementary Fig. S2A-S2D, respectively. Only minor differences were seen on incubation at 37 (H4, 
Supplementary Fig. S2A) compared to 50C (H9, Supplementary Fig. S2D). At higher E:S, peaks eluting before 10 min were more intense (H9 vs. H7, Supplementary Fig. S2D 
and S2C, respectively). Certain peaks eluting before 10 min were more intense at pH 7.0 (H8, Supplementary Fig. S2B), than at pH 8.0 (H9, Supplementary Fig. S2D). 
Supplementary Fig. S2. Reverse phase ultra-performance liquid chromatographic (RP-UPLC) profile of the -lactalbumin (-La) hydrolyzates generated with elastase at (A) pH 8.5, 37C, E:S 2% (H4), (B) pH 7.0, 50C, E:S 2% (H7), (C) pH 8.5, 
50C, E:S 1% (H8) and (D) pH 8.5, 50C, E:S 2% (H9). Peptide peaks highlighted with an arrow show major differences within the hydrolyzates. 
